Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Trestione, also known as 7α-methyl-19-norandrostenedione (MENT dione), is a synthetic anabolic-androgenic steroid (AAS) and a derivative of 19-nortestosterone (nandrolone). It functions as a prohormone for trestolone (7α-methyl-19-nortestosterone; MENT), an experimental androgen/anabolic steroid and progestogen. Trestolone acts as a high-affinity agonist of the androgen receptor and also exhibits potent progestogenic activity by binding to the progesterone receptor. This dual agonism leads to antigonadotropic effects by inhibiting the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn suppresses spermatogenesis and can induce temporary infertility. Trestolone is not a substrate for 5α-reductase, contributing to a high anabolic-to-androgenic ratio, and is a substrate for aromatase, producing 7α-methylestradiol as a metabolite. Trestione has been sold on the internet as a "dietary supplement" under the name Mentabolan.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on trestione.